Pediatrics · Endocrinology · General Practice · 2 h ago
Czechia’s Betty program screens 1% of children for type 1 diabetes
The nationwide Betty screening program tested 19,044 children aged 2–17.9 years in Czechia between April 2024 and February 2026. Multiple islet autoantibodies were detected in 0.39% of screened children without a first-degree relative with type 1 diabetes; the report describes feasibility, not evidence that screening improves health outcomes.
- 19,044 children screened across 270 sites in Czechia.
- Multiple autoantibodies found in 0.39% of the general population.
- Most staged confirmed cases were classified as Stage 1.
- Implementation results do not establish screening benefits or harms.
The Betty project is a nationwide childhood type 1 diabetes screening program in Czechia, established within the European EDENT1FI initiative. It uses a two-step test for islet autoantibodies, followed by venous confirmation when screening is positive. Between April 2024 and February 2026, the program collected 19,044 capillary samples—about 1% of the paediatric population—at 270 sites, mostly in primary care; 4.1% of samples came from home sampling. Nearly 90% of participants had no first-degree relative with type 1 diabetes.
Multiple autoantibodies were found in 0.39% of children in the general population (95% CI, 0.30%–0.51%) and 2.8% of first-degree relatives (95% CI, 2.1%–3.7%). Of 201 children with a non-negative capillary screen, 102 had early-stage type 1 diabetes confirmed by venous testing. Among 83 whose stage was assessed, 77 (93%) were in Stage 1, four (4.8%) in Stage 2 and two (2.4%) in Stage 3. Seven other screen-identified children developed Stage 3 disease before staging was completed.
The authors report that the program reached its initial population target and that families attending staging and education visits consented to long-term follow-up. These early implementation findings support feasibility; they do not establish the clinical benefits, harms or cost-effectiveness of routine population screening. The report describes a screening initiative and its initial results, rather than a comparison of health outcomes.
In practice
This report shows that a two-step islet autoantibody screening program can reach a substantial paediatric population through sites mainly in primary care, and that screening can identify children with confirmed multiple autoantibodies and early-stage type 1 diabetes. It does not show that population screening improves outcomes, reduces complications, or is cost-effective; the reported results cover about 1% of Czech children and are an initial program assessment. They do not, by themselves, justify changing routine screening practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Diabetes, Obesity and Metabolism: Population‐Based Screening for Type 1 Diabetes in Czechia: Results From the First 1% of the Paediatric Population ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.